[{"countryName":"Worldwide","languageLinks":[{"languageName":"English","languageUrl":"/en.html"}]},{"countryName":"USA","languageLinks":[{"languageName":"English","languageUrl":"/en-us.html"}]},{"countryName":"Japan","languageLinks":[{"languageName":"Japanese","languageUrl":"/jp/ja.html"}]}]
The link you have selected will take you outside of the Roche Sequencing USA website.
AVENIO Tumor Tissue Analysis Kits
Overview
AVENIO Tumor Tissue Analysis Kits are a portfolio of NGS assays that provide in-house tumor profiling, comprehensive genomic profiling (CGP), and surveillance & monitoring for clinical research. Through an optimized, end-to-end workflow, the kits offer a versatile solution to evaluate DNA extracted from formalin-fixed paraffin-embedded (FFPE) tissue samples.
Key Advantages of AVENIO Tumor Tissue Analysis Kits
- All four mutation classes (SNVs, indels, fusions and CNVs) in a single DNA workflow with exceptional sensitivity and specificity1
- 99% success rate for FFPE tissue samples that pass input QC testing using the AVENIO QC kit included with AVENIO tumor tissue assays
- A streamlined, end-to-end workflow from extraction to analysis and reporting in 5 days
- An integrated solution that includes reagents, intuitive analysis and reporting to facilitate in-house adoption of high-performance NGS oncology research
Benefits of AVENIO Tumor Tissue Targeted, Expanded and Surveillance Kits:
- Matched tissue and ctDNA panels (same genes, gene regions and hybrid-capture workflow) to facilitate concordance analysis
- Flexibility to switch between tissue and plasma to support a variety of research applications
Benefits of AVENIO Tumor Tissue CGP Kit
- Designed to match the 324-gene FoundationOne® CDx panel content
- Detects genomic signatures: TMB, MSI and LOH
AVENIO Tumor Tissue
CGP Kit
Designed to match the content of the 324 gene FoundationOne® CDx panel, the assay detects four classes of genomic alterations as well as genomic signatures: TMB, MSI, LOH.
AVENIO Tumor Tissue
Targeted Kit
A 17 gene (81kb) pan-cancer assay that contains guideline-aligned biomarkers, including those identified by the U.S. National Comprehensive Cancer Network (NCCN).2
AVENIO Tumor Tissue
Expanded Kit
A 77 gene (192kb) pan-cancer assay that contains 17 genes in the NCCN and other guidelines, plus 60 emerging biomarkers investigated in clinical research.
AVENIO Tumor Tissue
Surveillance Kit
A 197 gene (198kb) assay, containing 17 NCCN guideline-aligned genes, plus 471 frequently mutated disease-associated regions across 197 genes; optimized for longitudinal monitoring of tumor burden in lung and colorectal cancer.
- Data on file.
- National Comprehensive Cancer Network. October 15, 2016.